EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Open Access · CC BY 4.0

Fully intravenous split-dose administration of the oncolytic adenovirus TILT-123 in advanced solid tumors

Elise Jirovec, Katriina J Jalkanen, Dafne C A Quixabeira, James H A Clubb, Tuomo Alanko, Tatiana V Kudling, Victor Arias, Santeri A Pakola, Susanna Grönberg-Vähä-Koskela, Mirte van der Heijden, Anniina Färkkilä, Juha Kononen und 12 weitere

Molecular Therapy · 2026

DOI: 10.1016/j.ymthe.2026.05.007 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Molecular Therapy, 2026. Verfasst von Elise Jirovec und 23 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland. Hauptthemen laut MEDLINE: Adenoviridae, Oncolytic Viruses, Neoplasms, Oncolytic Virotherapy. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Research Council of Finland, Cancer Foundation Finland, Sigrid Jusélius Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

TILT-123 (Ad5/3-E2F-d24-hTNFα-IRES-hIL2, igrelimogene litadenorepvec) is a chimeric oncolytic adenovirus engineered to selectively replicate in tumor cells and express tumor necrosis factor (TNF) and interleukin-2 (IL-2). While oncolytic viruses are commonly administered intratumorally, this approach often restricts practical applicability. Intravenous delivery is less invasive and offers a more practical alternative; however, systemic immune barriers challenge effective tumor targeting. In a cohort of a phase 1 clinical trial, six patients with advanced solid tumors who had exhausted standard treatments received two intravenous doses of TILT-123 (split-dose), per treatment day across seven cycles. Safety was the primary objective, while efficacy outcomes were exploratory and assessed using positron emission tomography/-computed tomography (PET/CT) imaging, along with overall survival. Split-dosing was safe, with chills, fever, fatigue, and lymphocyte reduction being the most common treatment-related events. In imaging, the disease control rate was 83.3% according to PET criteria and 33.3% by RECIST 1.1. The median overall survival was 198 days. Split-dosing increased the area under the curve of TILT-123 and amplified systemic cytokine responses. Proteomic analysis of serum and neutralizing antibody profiling indicated that enhanced humoral immune activity was associated with shorter overall survival. Post-treatment biopsies confirmed virus presence and alterations in immune cell composition. These findings support further evaluation of intravenous TILT-123 administration in clinical trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AdenoviridaeOncolytic VirusesNeoplasmsOncolytic VirotherapyGenetic VectorsHumansFemaleMaleMiddle AgedAgedTreatment OutcomeAdministration, IntravenousInterleukin-2Positron Emission Tomography Computed TomographyAdultTumor Necrosis Factor-alpha

Stichwörter der Autor:innen

immunotherapyinterleukin-2intravenous deliveryoncolytic adenovirussolid tumorssplit-dosingtumor necrosis factor

Substanzen

Interleukin-2Tumor Necrosis Factor-alpha

Autor:innen und Institutionen

  • Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland.
  • Comprehensive Cancer Center, HUS Helsinki University Hospital, Helsinki, Finland.
  • Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland; TILT Biotherapeutics Oy, Helsinki, Finland.
  • Docrates Cancer Center, Helsinki, Finland.
  • Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland; Comprehensive Cancer Center, HUS Helsinki University Hospital, Helsinki, Finland.
  • Research Programs in Systems Oncology, Faculty of Medicine, University of Helsinki, Helsinki, Finland; Institute for Molecular Medicine Finland, Helsinki Institute Sciences, University of Helsinki, Helsinki, Finland; Cl…

Förderung

  • Research Council of Finland
  • Cancer Foundation Finland
  • Sigrid Jusélius Foundation
  • Finnish Red Cross Blood Service
  • Jane and Aatos Erkko Fundation

Zitieren

APA

Jirovec, E., Jalkanen, K. J., Quixabeira, D. C. A., Clubb, J. H. A., Alanko, T., Kudling, T. V., Arias, V., Pakola, S. A., Grönberg-Vähä-Koskela, S., van der Heijden, M., Färkkilä, A., Kononen, J., Sormunen, J., Kemppainen, J., Hellesuo, M., Haybout, L., Kistler, C., Sorsa, S., Havunen, R., …, & Hemminki, A. (2026). Fully intravenous split-dose administration of the oncolytic adenovirus TILT-123 in advanced solid tumors. Molecular Therapy. https://doi.org/10.1016/j.ymthe.2026.05.007

Vancouver

Jirovec E, Jalkanen KJ, Quixabeira DCA, Clubb JHA, Alanko T, Kudling TV, et al. Fully intravenous split-dose administration of the oncolytic adenovirus TILT-123 in advanced solid tumors. Molecular Therapy. 2026. doi:10.1016/j.ymthe.2026.05.007

BibTeX
@article{Jirovec2026,
  author = {Jirovec, Elise and Jalkanen, Katriina J and Quixabeira, Dafne C A and Clubb, James H A and Alanko, Tuomo and Kudling, Tatiana V and Arias, Victor and Pakola, Santeri A and Grönberg-Vähä-Koskela, Susanna and van der Heijden, Mirte and Färkkilä, Anniina and Kononen, Juha and Sormunen, Jorma and Kemppainen, Jukka and Hellesuo, Maria and Haybout, Lyna and Kistler, Claudia and Sorsa, Suvi and Havunen, Riikka and Santos, Joao M and Kanerva, Anna and Cervera-Carrascon, Victor and Hemminki, Otto and Hemminki, Akseli},
  title = {Fully intravenous split-dose administration of the oncolytic adenovirus TILT-123 in advanced solid tumors},
  journal = {Molecular Therapy},
  year = {2026},
  doi = {10.1016/j.ymthe.2026.05.007}
}
Kostenlos starten →